Premium
How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon‐based therapy with second wave direct acting antivirals
Author(s) -
Serfaty Lawrence
Publication year - 2015
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.12722
Subject(s) - daclatasvir , simeprevir , sofosbuvir , medicine , ribavirin , pegylated interferon , ns5a , regimen , virology , hepatitis c virus , ns3 , hepatitis c , combination therapy , gastroenterology , hepacivirus , virus
Second wave direct acting antivirals such as sofosbuvir, simeprevir and daclatasvir can be combined with pegylated interferon alpha and ribavirin ( PEG ‐ IFN / RBV ) as triple therapy in patients with hepatitis C virus ( HCV ) infection. In patients with HCV genotype 1 ( HCV ‐1), a PEG ‐ IFN / RBV ‐based regimen with sofosbuvir is highly effective but the presence of cirrhosis and the non‐ CC IFNL 3 genotype have been associated with a poorer response. A PEG ‐ IFN / RBV ‐based regimen with simeprevir or daclatasvir is based on response‐guided therapy and its efficacy depends on predictors of response to IFN . HCV ‐1 subtype is also a major predictor of response. In HCV ‐1a infected patients, the K80Q mutation in NS 3 or the presence of NS 5A variants at baseline are associated with poor response with simeprevir‐ or daclatasvir‐containing regimens respectively. Thus, these regimens should be only used in HCV ‐1b patients with good predictors of response to IFN .